select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Drug Overdose-Pipeline Review, H2 2017

Drug Overdose-Pipeline Review, H2 2017


  • Products Id :- GMDHC9704IDB
  • |
  • Pages: 48
  • |
  • September 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Drug Overdose-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose-Pipeline Review, H2 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).

The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose-Overview

Drug Overdose-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose-Companies Involved in Therapeutics Development

Fab'entech SA

Insys Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

Drug Overdose-Drug Profiles

Antibody for Poisoning, Drug Overdose and Opioid Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBT-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Drug Overdose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Drug Overdose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug Overdose-Dormant Projects

Drug Overdose-Discontinued Products

Drug Overdose-Product Development Milestones

Featured News & Press Releases

Aug 10, 2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization

Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent

Jun 18, 2017: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy for the Treatment of Local Anesthetic Systemic Toxicity

Jun 06, 2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose-Current Medical Research and Opinion Journal

Apr 24, 2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada

Apr 11, 2017: Ontario ministries make NARCAN Nasal Spray available to general public

Apr 10, 2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities

Mar 27, 2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray

Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose

Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel's Co-Gel Buccal Naloxone (Exonal)

Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents

Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.

Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray

Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas

Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Drug Overdose, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Drug Overdose, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Drug Overdose-Pipeline by Fab'entech SA, H2 2017

Drug Overdose-Pipeline by Insys Therapeutics Inc, H2 2017

Drug Overdose-Pipeline by Klaria Pharma Holding AB, H2 2017

Drug Overdose-Pipeline by Opiant Pharmaceuticals Inc, H2 2017

Drug Overdose-Dormant Projects, H2 2017

Drug Overdose-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Fab'entech SA

Insys Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

Drug Overdose Therapeutic Products under Development, Key Players in Drug Overdose Therapeutics, Drug Overdose Pipeline Overview, Drug Overdose Pipeline, Drug Overdose Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com